Cargando…
Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
Trastuzumab is a recombinant humanized monoclonal antibody that selectively targets the extra-cellular domain of the HER2 receptor. It was approved by the FDA in September 1998 as the first targeted therapy for HER2-positive metastatic breast cancer, and has since led to significant improvements in...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327515/ https://www.ncbi.nlm.nih.gov/pubmed/22518088 http://dx.doi.org/10.4137/CMO.S6460 |
_version_ | 1782229666731393024 |
---|---|
author | Jeyakumar, Alwin Younis, Tallal |
author_facet | Jeyakumar, Alwin Younis, Tallal |
author_sort | Jeyakumar, Alwin |
collection | PubMed |
description | Trastuzumab is a recombinant humanized monoclonal antibody that selectively targets the extra-cellular domain of the HER2 receptor. It was approved by the FDA in September 1998 as the first targeted therapy for HER2-positive metastatic breast cancer, and has since led to significant improvements in the overall prognosis for patients with HER2-positive metastatic disease. The favourable benefit/risk profile associated with palliative trastuzumab has been demonstrated in a number of clinical trials that examined trastusumab as monotherapy or in combination with chemotherapy, endocrine therapy and other HER2 targeted agents. The clinical benefits of trastuzumab, however should also be examined within the context of its significant drug acquisition costs. This review highlights the significant findings from the landmark clinical trials of trastuzumab for metastatic HER2-positive breast cancer, and the potential “value for money” associated with its use in clinical practice. |
format | Online Article Text |
id | pubmed-3327515 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-33275152012-04-19 Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations Jeyakumar, Alwin Younis, Tallal Clin Med Insights Oncol Expert Review Trastuzumab is a recombinant humanized monoclonal antibody that selectively targets the extra-cellular domain of the HER2 receptor. It was approved by the FDA in September 1998 as the first targeted therapy for HER2-positive metastatic breast cancer, and has since led to significant improvements in the overall prognosis for patients with HER2-positive metastatic disease. The favourable benefit/risk profile associated with palliative trastuzumab has been demonstrated in a number of clinical trials that examined trastusumab as monotherapy or in combination with chemotherapy, endocrine therapy and other HER2 targeted agents. The clinical benefits of trastuzumab, however should also be examined within the context of its significant drug acquisition costs. This review highlights the significant findings from the landmark clinical trials of trastuzumab for metastatic HER2-positive breast cancer, and the potential “value for money” associated with its use in clinical practice. Libertas Academica 2012-04-03 /pmc/articles/PMC3327515/ /pubmed/22518088 http://dx.doi.org/10.4137/CMO.S6460 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. |
spellingShingle | Expert Review Jeyakumar, Alwin Younis, Tallal Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations |
title | Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations |
title_full | Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations |
title_fullStr | Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations |
title_full_unstemmed | Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations |
title_short | Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations |
title_sort | trastuzumab for her2-positive metastatic breast cancer: clinical and economic considerations |
topic | Expert Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327515/ https://www.ncbi.nlm.nih.gov/pubmed/22518088 http://dx.doi.org/10.4137/CMO.S6460 |
work_keys_str_mv | AT jeyakumaralwin trastuzumabforher2positivemetastaticbreastcancerclinicalandeconomicconsiderations AT younistallal trastuzumabforher2positivemetastaticbreastcancerclinicalandeconomicconsiderations |